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ORIGINAL ARTICLEDual Effects of Bisphosphonates
on Ectopic Skin and Vascular Soft
Tissue Mineralization versus Bone
Microarchitecture in a Mouse Model of
Generalized Arterial Calcification of
Infancy
Qiaoli Li1, Joshua Kingman1, John P. Sundberg2, Michael A. Levine3 and Jouni Uitto1Generalized arterial calcification of infancy is an intractable ectopic mineralization disorder caused by muta-
tions in the ENPP1 gene, resulting in reduced plasma inorganic pyrophosphate (PPi) levels. We previously
characterized the Enpp1asj mutant mouse as a model of generalized arterial calcification of infancy, and we have
now explored the potential efficacy of bisphosphonates, nonhydrolyzable PPi analogs, in preventing ectopic
mineralization in these mice. The mice were maintained on either basic diet (control) or diets containing eti-
dronate or alendronate in three different concentrations (experimental). Considering low bioavailability of
bisphosphonates when administered orally, subsequent studies tested the mice with subcutaneous injections
of etidronate. The treatments were initiated at 4 weeks of age, and the degree of mineralization was assessed at
12 weeks of age by quantitation of calcium deposits in the muzzle skin containing dermal sheath of vibrissae
and in aorta. We found that bisphosphonate treatments significantly reduced mineralization in skin and aorta.
These changes in treated mice were accompanied with restoration of their bone microarchitecture, determined
by microcomputed tomography. The inhibitory capacity of bisphosphonates, with mechanistic implications,
was confirmed in a cell-based mineralization assay in vitro. Collectively, these results suggest that
bisphosphonate treatment may be beneficial by a dual effect for preventing ectopic soft tissue mineralization
while correcting decreased bone mineralization in generalized arterial calcification of infancy caused by ENPP1
mutations.
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Generalized arterial calcification of infancy (GACI) (OMIM
20800) is an autosomal recessive disorder characterized by
ectopic mineralization of the cardiovascular system (Rutsch
et al., 2011). The deposition of calcium hydroxyapatite
initially on arterial blood vessels, but also on other soft con-
nective tissues, including skin, starts during fetal development,
and the disorder is often diagnosed by prenatal ultrasound. The
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12 months of life from cardiovascular complications. The
classic form of this disease, GACI type 1, is caused by muta-
tions in the ENPP1 gene (Ruf et al., 2005; Rutsch et al., 2003),
which encodes ectonucleotide pyrophosphatase/phosphodi-
esterase 1 (ENPP1), an enzyme that hydrolyzes adenosine
triphosphate to adenosine monophosphate and inorganic py-
rophosphate (PPi).Under normal physiologic conditions, PPi is
a powerful antimineralization factor and the physiological
ratio of PPi to inorganic phosphate (Pi) is required to prevent
spontaneous precipitation of calcium phosphate complexes
on soft connective tissues. Thus, as a result of loss-of-function
mutations in the ENPP1 gene, the synthesis of PPi is reduced,
resulting in a low PPi/Pi ratio that then allows the ectopic
mineralization processes to ensue. Loss-of-function ENPP1
mutations can also cause autosomal recessive hypo-
phosphatemic rickets (Lorenz-Depiereux et al., 2010), sug-
gesting an as-yet-elusive mechanism that balances arterial
calcification with bone mineralization. In addition, ENPP1
mutations have been identified in some patients with pseu-
doxanthoma elasticum (PXE), another ectopic mineralization
disorder, but most cases with this disorder harbor mutations in
the ABCC6 gene (Li et al., 2012; Nitschke et al., 2012).estigative Dermatology. www.jidonline.org 275
Table 1. Experimental groups of Enpp1asj mice by
genotype and treatment1
Group Genotype
No. of mice
examined
(MDF) Treatment
Set 1 (p.o.)
A asj 9 (6 þ 3) Control diet
B asj 9 (6 þ 3) Diet containing 1 ETD
C asj 6 (1 þ 5) Diet containing 5 ETD
D asj 8 (5 þ 3) Diet containing 12 ETD
E asj 6 (4 þ 2) Diet containing 1 AST
F asj 7 (3 þ 4) Diet containing 5 AST
G asj 8 (4 þ 4) Diet containing 12 AST
H WT 9 (6 þ 3) Control diet
Set 2 (s.c.)
I asj 7 (3 þ 4) Saline
J asj 8 (3 þ 5) 0.01 ETD
K asj 11 (8 þ 3) 0.12 ETD
Abbreviations: AST, alendronate sodium trihydrate; ETD, etidronate
disodium; F, female; M, male; p.o., perioral; s.c., subcutaneous.
1The mice were placed on either bisphosphonate-containing diets (set 1)
or injected with ETD subcutaneously (set 2) at 4 weeks of age and fol-
lowed for another 8 weeks. The mice were killed at the age of 12 weeks
for histopathological analysis. Control diet: acceleration diet TD.00442.
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276There is no effective or specific treatment for GACI. A few
studies have suggested that administration of bisphospho-
nates might be helpful in counteracting the ectopic miner-
alization in GACI; however, there is no consensus about the
efficacy of these compounds. In some studies, an apparent
improvement has been reported, whereas in other cases there
has been very little, if any, effect (Edouard et al., 2011;
Galletti et al., 2011; Ramjan et al., 2009; Rutsch et al.,
2008). Bisphosphonates have also been reported to be
accompanied by severe side effects, particularly on the
development of bones (Otero et al., 2013; Silverman et al.,
1994; Thomas et al., 1995). These differences can possibly
be explained, in part, by the types and doses of bisphosph-
onates used and the route of administration that vary
considerably in different studies.
Bisphosphonates are structural analogs of PPi in which the
oxygen linkage to phosphonate (PO3) groups is replaced by a
carbon molecule making them stable. The bisphosphonates
have two side groups (R1, R2) that determine their potency as
well as their pharmacologic characteristics. There are two
classes of bisphosphonates, that is, those containing nitrogen
in the side groups and nonenitrogen-containing forms.
Bisphosphonates have two principal activities relating to
mineralization: (a) they can serve as an antimineralization
factor, and (b) they are inhibitors of osteoclast activity. The
latter property is the basis for their use in the treatment of bone
diseases, particularly osteoporosis, but also for Paget’s disease
and bonemetastases (Rodan and Fleisch, 1996; Russell, 2006;
Uludag, 2002). The first-generation bisphosphonates, as
exemplified by etidronate (ETD), a nonenitrogen-containing
bisphosphonate, display considerable antimineralization ac-
tivities but are less potent inhibitors of osteoclasts than
currently used third-generation nitrogen-containing
bisphosphonates, such as alendronate (AST). In this study, we
have tested the potential use of these prototypic bisphospho-
nates, ETD and AST, for the treatment of GACI. Specifically,
these bisphosphonates were administered orally or by subcu-
taneous injections to Enpp1asj mice (hereafter referred to
as asj), a mouse model of GACI (Li et al., 2013). These mice
harbor a homozygous missense mutation in the Enpp1 gene
that results inmarkedly reduced ENPP1 enzymatic activity and
lowered plasmaPPi concentration that subsequently allows for
ectopicmineralization of soft connective tissues in the skin and
arterial blood vessels to ensue (Li et al., 2013). In this study, we
investigated the effects of bisphosphonates in asj mice on
ectopicmineralization in skin andvascular tissues aswell as on
bone microarchitecture and mineralization.
RESULTS
GACI is a devastating ectopic mineralization disorder with
the demise of affected individuals usually during the first year
of life. There is no effective or specific treatment for this
disorder. In this study, we tested the hypothesis that
bisphosphonates might counteract the ectopic mineralization
in skin and vascular tissues, while enhancing bone mineral-
ization, using asj mice as a preclinical platform.
Oral administration of bisphosphonates to asj mice
In the first set of experiments (set 1), two different prototypic
bisphosphonates, ETD or AST, in three different concentrationsJournal of Investigative Dermatology (2016), Volume 136that were calculated to correspond to 1, 5, and 12 of the
corresponding human dose used for the treatment of osteopo-
rosis, respectively,were tested byoral administration.Groups of
asj mice and wild-type (WT) mice were kept on “acceleration
diet,” which facilitates the mineralization process in these mice
(Li et al., 2013) without bisphosphonates serving as positive and
negative controls of mineralization. For the experimental
groups, all mice were kept on the acceleration diet with or
without bisphosphonates (see Table 1). The degree of minerali-
zation was first assessed by histopathologic examination of the
dermal sheath of vibrissae, a connective tissue capsule sur-
rounding the bulb of vibrissae in the muzzle skin, which serves
as an early progressive biomarker of overall mineralization in
these mice (Li et al., 2013).
Histopathologic examination of the asj mice on acceler-
ation diet revealed extensive mineralization, whereas no
evidence of mineralization was noted in WT mice on the
same diet (Figure 1). Evidence of mineralization was also
noted in the vibrissae and aorta of asj mice treated with
various doses of ETD or AST, but histopathologic examina-
tion suggested a lesser extent of mineral deposits. The
presence of tissue mineralization in asj mice was also
examined semiquantitatively by histopathology of kidneys,
heart, descending thoracic aorta, and eyes of the asj mice.
The majority of asj mice treated with either ETD or AST
demonstrated mineralization, and no statistical difference in
the proportional mineralization in the kidney, heart, and the
eyes was noted (Supplementary Table S1 online). It should
be noted that the values in Supplementary Table S1 report
the presence of any degree of mineralization. On the other
hand, as shown in Figure 1, the degree of mineralization
was reduced by the bisphosphonate treatments, although
this treatment did not result in the complete absence of
mineralization in most cases. Therefore, the values in
Supplementary Table S1, which reflect semiquantitative
Figure 1. Histopathologic demonstration that bisphosphonate treatment prevents ectopic soft tissue mineralization in asj mice. The asj mice develop ectopic
mineralization of the dermal sheath of vibrissae (a) and aorta (b) when examined at 12 weeks of age by histopathology with Alizarin red stain (group A). Note
that the corresponding wild-type mice have no evidence of mineralization (group H). Feeding the asj mice with diet supplemented with 12 ETD (group D) or
12 AST (group G), and injecting the asjmice with 0.12 ETD (group K) markedly reduced the mineral content of the dermal sheath of vibrissae and aorta. AST,
alendronate sodium trihydrate; ETD, etidronate disodium; p.o., perioral; s.c., subcutaneous. Scale bar ¼ 0.4 mm.
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significantly.
Subcutaneous administration of bisphosphonates to asj mice
In the second set of experiments (set 2), asj mice, again kept
on the acceleration diet, were injected with ETD subcuta-
neously at 4 weeks of age, followed by twice per week in-
jections up to 12 weeks of age. Two dosages of ETD were
delivered, 0.01 and 0.12 (groups J and K) of the doses
administered orally, based on the assumptions that the ab-
sorption of ETD from oral feeding is only 1% or less (Rodan
and Fleisch, 1996; Russell, 2006; Uludag, 2002), whereas
subcutaneous injection would result in 100% absorption of
the drug. As a control, a group of mice was injected with
saline (group I). Histopathologic examination revealed
reduction of the mineralization of dermal sheath of vibrissae
and abdominal aorta in all mice to various degrees (Figure 1),
whereas the presence of mineralization in the kidney, heart,
descending thoracic aorta, and eyes in mice injected with
ETD was not significantly different from those in mice
injected with saline (Supplementary Table S1).
Quantitation of ectopic mineralization in the skin and aorta
by calcium assay
To quantitate the degree of mineralization in the skin and
abdominal aorta in different groups of mice, tissue samples
were obtained,mineral depositswere solubilized, and calcium
content was quantitatively measured by a chemical assay.
These mineral deposits consist of calcium hydroxyapatite, the
Ca/P ratio being approximately 2:1 (Kavukcuoglu et al., 2012).
The amount of calcium in the muzzle skin containing the
dermal sheath of vibrissaewas significantly reduced in allmice
treated with ETD or AST by oral administration (Figure 2a, set
1). A similar assay of calcium in the vibrissae of mice injected
subcutaneously with ETD indicated an approximately 30%
reduction with the higher 0.12 dose (Figure 2c, set 2). The
extent of mineralization was also determined by the calcium
assay in the abdominal aorta from the same mice (Figure 2band d). These analyses revealed a relatively high baseline level
of calcium content in the aorta of WT mice (group H;
Figure 2b), but there was no evidence of mineralization by
histology (Figure 1b).Oral feeding of ETD significantly reduced
themineralization of aorta, the reductionwith the highest dose
(12) being approximately 50% of the mice on the same diet
but without bisphosphonate. Similarly, feeding of ASTwith 5
or 12 dosages resulted in significant reduction in the calcium
content in muzzle skin. Subcutaneous injection of ETD with
the higher dosage of ETD (0.12) resulted in significant
reduction of calcium content in muzzle skin and abdominal
aorta (Figure 2d, set 2). Thus, the administration of ETD or AST
orally or ETD by subcutaneous injections reduces the miner-
alization of muzzle skin as well as in aorta, as suggested by
histopathologic observations and quantitated by the direct
chemical assay of calcium content in these tissues.
The effects of bisphosphonate administration on serum
calcium and phosphate concentrations were also deter-
mined. In majority of cases, the treatment of the asj mice
orally or subcutaneously did not alter the serum calcium or
phosphate concentrations or change the Ca/Pi ratio
(Supplementary Table S2 online).
Effects of bisphosphonates on bone microarchitecture and
mineralization
Because bisphosphonates pose both antimineralization and
anti-osteoclastic activities, and they have been primarily used
for the treatment of bone disorders, such as osteoporosis, we
evaluated the morphometric microarchitecture of the trabec-
ular and cortical bones of femur in treated asj mice by
microcomputed tomography analysis. The WT mice and asj
mice on the acceleration diet, the asjmice on the same diet but
supplemented with 12 ETD or 12 AST in their diets, as well
as asj mice, also kept on acceleration diet, receiving subcu-
taneous injectionswith 0.12 ETDwere analyzed. Therewere
marked differences between the male and female mice on
bone trabecular microarchitecture (Figure 3), which iswww.jidonline.org 277
Figure 2. Bisphosphonate treatment reduces ectopic soft tissue
mineralization as determined by the direct chemical assay of calcium. (a, c)
Skin biopsies containing the dermal sheath of vibrissae; (b, d) abdominal
aorta. Note the significantly elevated calcium content in asj mice as
compared with the WT mice (group A vs. H; þP < 0.01). Treatment of asj
mice with diet supplemented with different concentrations of ETD or AST
(groups BeD and EeG, respectively; p.o.) resulted in a significant reduction
in the calcium content in comparison with the asj mice on control diet (group
A; *P < 0.05, þP < 0.01). Injecting of mice subcutaneously (s.c.) with 0.12
ETD (group K), but not with 0.01 ETD (group J), significantly reduced the
calcium content of the skin and aorta as compared with mice injected with
saline (group I). Mean  SE; n ¼ 6e11 mice per group. AST, alendronate
sodium trihydrate; ETD, etidronate disodium; p.o., perioral; s.c.,
subcutaneous; WT, wild-type.
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278consistent with previous publications (Bouleftour et al., 2014;
Pennypacker et al., 2009). Therefore, sex-matched compari-
sons on bone microarchitecture were performed between asj
mice and WT mice as well as those treated with bisphospho-
nates orally or subcutaneously. Drastic differences on bone
mineralization were found between WTand asj mice, as well
as between asj mice on acceleration diet and those treated
with bisphosphonates (Figure 3, upper panel). These changes
of bone morphometric microarchitecture were subsequently
quantified using manufacturer-provided software (Table 2).
The asjmice of both sexes have reduced bone mineralization,
trabecular bonemass, and cortical thickness as comparedwith
WT mice on the same diet (Table 2, groups A vs. H). TheseJournal of Investigative Dermatology (2016), Volume 136observations are in agreement with those seen in Enpp1
knockout mice (Enpp1tm1Gdg) (Hajjawi et al., 2014;
Mackenzie et al., 2012). The distal femoral bone volume
fraction was increased as a result of bisphosphonate treat-
ments, corresponding to the increased trabecular bone min-
eral density by approximately twofold in treated mice.
Trabecular number in asj mice treated with bisphosphonates
increased significantly, whereas trabecular separation was
significantly less in bisphosphonate-treated mice. The struc-
ture model index is significantly less, whereas connectivity
density was significantly higher (approximately three- to
fourfold) in sex-matchedmice treatedwith bisphosphonates as
compared with untreated asj mice (Table 2). Treated asj mice
restored trabecular parameters close to those in the controlWT
mice. The effects between 12 ETD and 12 AST feeding
groups were also compared, the 12 AST treated mice had
significantly higher bone mineral density and trabecular
number, whereas trabecular separation is significantly less
(Table 2). These results attest to the stronger potency of AST
than ETD in anti-osteoclastic activities. The asj mice that
received 0.01 ETD subcutaneous injections had most of the
bone parameters similar to the asjmice treated with 12 ETD
orally (Table 2). The cortical parameters were unchanged in
treated mice as compared with untreated asj mice (Table 2).
Collectively, microcomputed tomography analysis of the fe-
murs disclosed changes of bone microarchitecture in treated
asj mice compared with sex-matched asj control mice as a
result of bisphosphonates treatment, observations consistent
with previous publications.
Demonstration of antimineralization effects of
bisphosphonates in an in vitro assay
To gain insight into the potential pathomechanisms as to how
bisphosphonates might interfere with mineral deposition
in vivo, an in vitro mineralization assay was utilized. Spe-
cifically, fibroblasts in monolayer culture were incubated at
approximately 80% confluency in a DMEM culture medium,
and 2 mM Pi is added at day 0. During the subsequent 10
days of incubation, significant cell layereassociated miner-
alization could be observed, as determined by phase contrast
microscopy of the cells, and by direct assay of calcium
associated with the cell layer and corrected for the protein
content (Figure 4A). A dramatic, approximately 49-fold in-
crease in the degree of mineralization was noted in cultures
on addition of Pi. The addition of various concentrations of
PPi revealed a dramatic inhibition of the mineralization on
cell cultures with 10 or 100 mM, whereas concentrations 1
mM or lower have no effect. Similarly, the addition of ETD
resulted in an essentially complete inhibition of calcium
deposition on the cells in 10 and 100 mM concentrations
(Figure 4B). A similar trend was noted with 10 and 100 mM
AST, although the inhibition of mineralization was not as
complete as with ETD.
DISCUSSION
GACI (OMIM 20800) is an autosomal recessive disease
characterized by severe vascular calcification in large- and
medium-sized arteries resulting in cardiovascular collapse
and death in the early postnatal period. GACI type 1, the
classic form, is caused by mutations in the ENPP1 gene that
Figure 3. Bisphosphonate treatment alters bone microarchitecture in asj mice as determined by mCT analysis. (a) Trabecular bone; (b) cortical bone. Regions
in the box outline the areas of bone where analysis was performed for images and morphometric parameters. Groups D, G, and K in which asjmice were treated
with bisphosphonates either by perioral (p.o.) or subcutaneous administration (s.c.) were compared with asjmice (group A) and WT mice (group H) on the same
diet but without bisphosphonates. Note the distinct difference between male (top row in each panel) and female (bottom row in each panel) asj mice on control
diet (group A), assessed by mCT scan. Treatment with bisphosphonates caused changes in femoral microarchitecture, as quantitatively detailed in Table 2
(n ¼ 8e11). AST, alendronate sodium trihydrate; ETD, etidronate disodium; mCT, microcomputed tomography; WT, wild-type.
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glycoprotein. ENPP1 is the primary source of extracellular
inorganic pyrophosphate (PPi) in the body. Under normal
physiologic conditions, PPi acts as a powerful anti-
mineralization factor (Nitschke and Rutsch, 2012b). The pa-
tients with GACI type 1 have previously been shown to have
a markedly reduced PPi/Pi ratio that would explain the severe
mineralization of arterial blood vessels and other soft con-
nective tissue, including the skin. Some patients with GACI
type 1 also develop hypophosphatemic rickets characterized
by reduced bone mineralization (Lorenz-Depiereux et al.,
2010). GACI type 2 is caused by mutations in the ABCC6
gene (Li et al., 2014; Nitschke et al., 2012) that encodes a
putative efflux transporter, ABCC6. Mutations in this gene
also cause PXE (OMIM 264800), another heritable ectopic
mineralization disorder with a late-onset, slowly progressive
disease. Recent studies have demonstrated considerable
genotypic and phenotypic overlap between PXE and GACI (Li
et al., 2012, 2014; Li and Uitto, 2013; Nitschke and Rutsch,
2012a). There is no effective treatment for these diseases with
considerable morbidity and mortality. Recently, patients with
PXE with ABCC6 mutations and the Abcc6/ mouse modelof PXE have been reported to have decreased extracellular
concentrations of nucleotide triphosphates and PPi through
an unknown mechanism (Jansen et al., 2013, 2014). The
identification of mutations both in ENPP1 and ABCC6 as
genetic etiologies for GACI therefore links the same
biochemical pathway to unregulated tissue mineralization in
both types of GACI.
The observations of decreased extracellular PPi levels in
patients with GACI or PXE caused by ENPP1 mutations have
led to the suggestion that administration of PPi or its analogs
to the patients could counteract the ectopic mineralization
(O’Neill et al., 2011). Bisphosphonates, which are stable,
nonhydrolyzable PPi analogs, are typically prescribed for the
treatment of osteoporosis to reduce fracture risk, preventing
bone loss primarily by the inhibition of osteoclast function.
Bisphosphonates also demonstrate antimineralization activ-
ities, and different chemical structures of bisphosphonates
determine their potency, mode of action, as well as their
pharmacologic characteristics. Etidronate, the first generation
of bisphosphonates favoring antimineralization property
over the antiosteoclastic activity, was the first molecule
used off-label in the treatment of fibrodysplasia ossificanswww.jidonline.org 279
Table 2. Bone phenotypes by microCT of the right femur of the mice1
Group2 Sex BMD (mg/cm3) BV/TV (%) Tb.Th (mm) Tb.N (1/mm) Tb.Sp (mm) SMI Conn.D (TV/mm3)
Trabecular bone
A M 57.5  17.2 3.3  0.7 27.6  3.1 3.9  0.1 256.6  7.7 3.3  0.1 49.8  14.2
A F 39.2  11.3 1.7  0.1 22.3  0.5 3.2  0.2 310.1  13.9 3.2  0.1 23.6  6.0
D M 96.9  9.5 5.0  0.8 28.1  2.0 4.1  0.1 239.5  9.2 2.7  0.2* 129.6  28.7*
D F 72.4  18.9 4.7  0.5þ 26.7  0.8* 4.1  0.2* 241.3  10.6* 2.7  0.1* 154.7  18.8þ
G M 107.7  12.6* 5.4  1.0 25.7  1.8 4.9  0.1þ,‡ 200.1  3.3þ,‡ 2.8  0.2* 164.3  32.9þ
G F 114.9  7.9þ,† 6.9  0.9þ 28.4  1.5* 4.6  0.1þ 213.5  6.2þ,† 2.5  0.1þ 234.9  30.0þ
H M 158.9  19.8þ 9.9  1.8þ 37.7  9.0 4.4  0.1þ 222.7  2.7þ 2.1  0.4þ 129.5  31.9*
H F 90.2  5.4* 4.1  0.6* 30.6  2.6* 3.6  0.1 277.5  9.2 3.1  0.1 90.9  5.9þ
K M 117.4  10.1þ 6.2  0.8* 26.5  0.9 4.7  0.1þ,† 208.1  6.7þ,† 2.5  0.2þ 209.6  33.2þ
K F 111.7  18.6* 6.6  1.4* 27.1  2.0 4.0  0.1* 245.4  5.0* 2.1  0.2þ,‡ 252.9  39.9þ
Group2 Sex BMD (mg/cm3) Ct.Porosity (%) Ct.pMOI (mm4) Ct.Th (mm)
Cortical bone
A M 1,044.1  7.4 11.0  0.5 0.28  0.03 128.2  6.9
A F 1,068.2  7.1 9.6  0.4 0.25  0.02 130.3  6.1
D M 1,054.5  1.3 10.1  0.6 0.37  0.02 137.5  5.8
D F 1,073.5  23.4 9.6  1.0 0.32  0.02 138.0  5.5
G M 1,050.3  12.8 10.1  0.7 0.31  0.02 132.0  6.5
G F 1,063.7  8.3 8.3  0.8 0.31  0.02 143.5  5.8
H M 1,072.0  6.7* 9.4  0.6 0.39  0.04* 161.0  6.1þ
H F 1,112.0  1.2* 7.6  0.2* 0.31  0.02 161.0  4.1*
K M 1,041.1  7.3 10.2  0.7 0.32  0.02 129.0  3.2
K F 1,052.7  9.0 9.9  0.4 0.27  0.02 127.7  3.4
Abbreviations: BMD, bone mineral density; BV/TV, relative bone volume; Conn.D, connectivity density; Ct.pMOI, cortical polar moment of inertia;
Ct.Porosity, cortical porosity; Ct.Th, cortical thickness; F, female; M, male; SMI, structure model index; Tb.N, trabecular number; Tb.Th, trabecular thickness;
Tb.Sp, trabecular separation (marrow thickness, mm).
Statistical significance in comparison with the asj mice of the same sex on acceleration diet (group A) is indicated: *P < 0.05, þP < 0.01.
Statistical significance in comparison with the asj mice fed on 12 ETD (group D) is indicated: †P < 0.05, ‡P < 0.01.
1Wild-type and asj mice were placed on acceleration diet at 4 weeks of age and maintained another 8 weeks. Groups of asj mice were either placed on
different diets supplemented with bisphosphonates or injected twice a week subcutaneously with saline or etidronate, for an additional 8 weeks. The right
femurs of the mice were analyzed by microcomputed tomography at 12 weeks of age. Values are expressed as mean  SE.
2For a description of different groups, see Table 1.
Q Li et al.
Treatment of GACI by Bisphosphonates
280progressiva (Francis and Valent, 2007), a severe soft tissue
mineralization disorder caused by mutations in the ACVR1
gene. Recently, bisphosphonates have been used off-label to
treat patients with ectopic mineralization, including new-
borns or infants with GACI type 1 with ENPP1 mutations or
GACI type 2 with ABCC6 mutations (Edouard et al., 2011;
Ramjan et al., 2009). In 2008, a retrospective observational
analysis of 55 patients with GACI revealed survival beyond
infancy with etidronate therapy (Rutsch et al., 2008), which
was corroborated by another study reporting that 15 of 22
GACI patients who received etidronate treatment survived
beyond infancy (Chong and Hutchins, 2008). However, other
studies have found no improvement in vascular mineraliza-
tion after bisphosphonates treatment (Galletti et al., 2011). A
recent case report has highlighted the severe skeletal toxicity
with paradoxical joint calcifications after protracted etidro-
nate therapy in a 7-year-old boy with GACI (Otero et al.,
2013). Furthermore, a number of studies have suggested
detrimental side effects of bisphosphonates treatment,
including the development of rickets or osteomalacia during
the protracted administration of bisphosphonates (Silverman
et al., 1994; Thomas et al., 1995). Taken together, the
above observations with limited available clinical data and
different patient outcomes make it difficult to determine ifJournal of Investigative Dermatology (2016), Volume 136bisphosphonates are helpful for the treatment of GACI. We,
therefore, assessed the effects of two bisphosphonate drugs
on ectopic soft tissue calcification and bone micro-
architecture in an asj mouse model of GACI.
This study was undertaken in asj mice with features that
recapitulate GACI in humans (Li et al., 2013) to test the ef-
fects of two bisphosphonates, ETD and AST, in the mineral-
ization processes. All mice were kept on “acceleration diet”
that accelerates the mineralization process elicited by the
absence of functional ENPP1 (Li et al., 2013). AST was
administered orally at lower molar doses than ETD due to its
approximately 1,000 times higher antiosteoclastic activity
(Rodan and Fleisch, 1996; Russell, 2006; Uludag, 2002). In
this study, we demonstrated that ETD and AST treatments
periorally significantly reduced mineralization in skin and
aorta in asjmice. When administered subcutaneously, ETD at
much lower dose (0.12) than when delivered orally resulted
in an approximately 30% reduction in ectopic mineralization
of the skin and aorta. Thus, subcutaneous administration
could be a better route of administration than oral intake for
the treatment of GACI due to higher bioavailability.
To explore potential mechanisms by which bisphospho-
nates might exert their antimineralization effects, an in vitro
mineralization assay was utilized. In this assay, the addition
Figure 4. Bisphosphonates prevent
mineralization in an in vitro culture
system. NIH3T3 cells were cultured
on 96-well plates in a DMEM medium
containing 10% FBS supplemented
with 2 mM Pi. At day 0, PPi, ETD, and
AST were added to some cultures at
concentrations indicated. At day 10,
the degree of mineralization was
assessed either (a) by phase contrast
light microscopy or (b) by the
chemical assay of calcium deposition
in the cell layer. *P < 0.01, compared
with ePi; þP < 0.01, compared
with þPi (mean  SE; n ¼ 4 cultures
in each group). AST, alendronate
sodium trihydrate; ETD, etidronate
disodium; FBS, fetal bovine serum; Pi,
inorganic phosphate; PPi, inorganic
pyrophosphate (sodium
pyrophosphate decahydrate). Scale
bar ¼ 0.1 mm.
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precipitation of calcium hydroxyapatite. The addition of
bisphosphonates resulted in abrupt inhibition of the miner-
alization process, similar to the addition of PPi, in the con-
centration range between 1 and 10 mM. These results
suggested that bisphosphonates, stable pyrophosphate ana-
logs, when reaching a certain stoichiometric ratio with Pi,
physically prevent the nucleation of calcium phosphate
crystals resulting in inhibition of tissue mineralization.
Because bisphosphonates, besides showing anti-
mineralization effects, also have antiosteoclastic activity, the
femurs of asj control mice and those treated with
bisphosphonates were analyzed for their bone micro-
architecture. Femur was selected as the target bone for
analysis, because several previous studies have focused on
the mineralization of this bone, thus providing appropriate
methodologies and relevant reference information for the
interpretation of our data (Mackenzie et al., 2012; Uveges
et al., 2009). The microcomputed tomography analysis of
femurs showed drastic sex-dependent differences on bone
mineralization between WTand asj mice without any special
treatment. As compared with WT mice, the asj mice had
reduced bone volume fraction, reduced trabecular and
cortical thickness, and reduced trabecular number, as re-
flected by the significant decrease in bone mineral density in
both trabecular bone and cortical bone. The bisphosphonatetreatment in asj mice orally or subcutaneously restored these
bone microarchitecture phenotypes to nearly similar to those
in WT mice. In addition, subcutaneous administration of ETD
provided stronger effects on bone microarchitecture than
when delivered orally, attesting to its better bioavailability.
Furthermore, AST was shown to be more potent than ETD
when supplemented in diets to cause changes in bone min-
eral density and bone microarchitecture. Collectively, the
results demonstrated changes in bone morphometry and
microarchitecture, attributable to bisphosphonate treatments.
Our results demonstrate the efficacy of bisphosphonates in
the treatment of GACI caused by ENPP1mutations. In addition
to preventing mineralization in soft connective tissues, an
abundance of evidence has been provided to show that
bisphosphonates are effective as a treatment for decreased
bone density and prevention of bone fracture in patients. As
compared with PXE, which has no clinical evidence of bone
abnormality, patients with GACI have reduced bone mineral-
ization with concomitant ectopic mineralization in vascular
tissues, suggesting dysregulated mineralization due to an as-
yet-unknown mechanism that balances arterial calcification
with bone mineralization (Rutsch et al., 2011). Some patients
with GACI develop hypophosphatemic rickets with a distinct
hypomineralizing phenotype. In addition, there are de-
scriptions of patients with a mild GACI phenotype who have
both arterial calcificationandconcomitant hypophosphatemiawww.jidonline.org 281
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282and hyperphosphaturia (Rutsch et al., 2008). One of the
mechanisms of decreased bone mineralization caused by
ENPP1 mutations is associated with elevated plasma FGF23
levels, which then mediates hypophosphatemic rickets
(Lorenz-Depiereux et al., 2010).Our studies using asjmice as a
model of GACI demonstrated dual beneficial effects of
bisphosphonates treatment in tissue mineralization and bone
mineralization. Bisphosphonate treatment in asjmice not only
counteracted soft tissue mineralization in skin and aorta, but
also restored bone mineralization parameters similar to those
in WT mice that should be considered as a beneficial effect.
Collectively, our results suggest that bisphosphonates may
be beneficial for preventing ectopic mineralization while
correcting decreased bone mineralization in GACI and PXE
caused by mutations in the ENPP1 gene. However, additional
long-term studies in mouse models should be conducted to
monitor for the development of side effects to ensure safety of
this approach. It is appropriate to point out that mineral
metabolism in the mice may differ from that in humans, and
some animals, and perhaps also humans, may be more prone
or resistant to these treatments. Consequently, the clinical
efficacy and potential side effects in humans remain to be
seen in forthcoming clinical trials.
MATERIALS AND METHODS
Mice and breeding
C57BL/6J-Enpp1asj/GrsrJ mice on a C57BL/6J background were ob-
tained from The Jackson Laboratory (Bar Harbor, ME). These mice
are referred to in this publication as the asj mice. The WT, hetero-
zygous, and homozygous asj mice were generated from heterozy-
gous matings. The mice were maintained on standard rodent
laboratory diet (Laboratory Autoclavable Rodent Diet 5010; PMI
Nutritional International, Brentwood, MO) under standard condi-
tions. All protocols were approved by the Institutional Animal Care
and Use Committee of Thomas Jefferson University.
Experimental design and treatments
For breeding purposes, the homozygous asj male and heterozygous
asj female mice were placed on standard rodent diet supplemented
with a fivefold increase in magnesium, to prevent these mice from
developing stiffened joints and tissue mineralization, thus capable of
breeding. The magnesium-enriched diet has been previously shown
to completely prevent connective tissue mineralization in a mouse
model of PXE (Abcc6e/e) (LaRusso et al., 2009; Li et al., 2009). The
heterozygous female mice, once pregnant, were switched to stan-
dard rodent diet. The offspring were genotyped, and the homozy-
gous asj mice, once weaned, were maintained on “acceleration
diet” throughout the experiment (Harlan Teklad, Rodent diet
TD.00442, Madison, WI). The “acceleration diet” is enriched in
phosphorus (2) and has reduced magnesium content (20%) in
comparison with the standard rodent diet. We have previously
shown that the “acceleration diet” is capable of accelerating the
onset and severity of tissue mineralization in the asj mice, thus
shortening the time required for acquisition of unequivocal results
(Li et al., 2013). Four-week-old WT and asj mice were either placed
on acceleration diet supplemented with ETD or AST (set 1) or
received subcutaneous injections of ETD (set 2) and maintained on
the same treatment regimen for an additional 8 weeks. The groups of
mice in the two sets, characterized by genotype and treatment, are
described in Table 1.Journal of Investigative Dermatology (2016), Volume 136In set 1, asj and WT mice at 4 weeks of age were fed either
“acceleration diet” (groups A and H) or the same diet supplemented
with either ETD or AST, 6e9 mice per group. ETD treatment con-
sisted of three groups: asjmice were fed with a dose calculated to be
equivalent to that used for the treatment of humans for osteoporosis
(20 mg/kg/day orally), that is, 8 mg etidronate disodium (Alfa Aesar,
Ward Hill, MA) per 100 g of diet (1 ETD), or 5- and 12-fold greater
doses (5 ETD and 12 ETD), respectively (groups B, C, and D).
AST treatment also consisted of three groups: asj mice were fed with
a dose equivalent to human (0.5 mg/kg/day orally), which received
0.2 mg alendronate sodium trihydrate (Alfa Aesar) per 100 g of diet
(1 AST), or a 5- and 12-fold increase of the human equivalent dose
(5 AST and 12 AST) (groups E, F, and G). After 8 weeks of
treatment, all mice were euthanized for tissue analysis.
In set 2, the asj mice were placed on the acceleration diet at 4
weeks of age, and injected with ETD subcutaneously, twice a week,
for a total of 8 weeks. Mice were weighed every 2 weeks to deter-
mine the appropriate treatment doses (on an mg/kg basis). Subcu-
taneous injections consisted of three groups: asj mice were injected
with (i) sterile saline, (ii) 0.01 ETD, or (iii) 0.12 ETD, 7e11 mice
per group (groups I, J, and K). The dose of 0.01 ETD was based on
the assumption of 1% of intestinal absorption of ETD, whereas 100%
absorption by subcutaneous injection (Rodan and Fleisch, 1996;
Russell, 2006; Uludag, 2002). All mice were euthanized at 12
weeks of age for tissue analysis.
Histopathological analysis
Muzzle skin biopsies (left side) and internal organs (liver, kidney,
heart, eyes, and descending thoracic aorta) from euthanized mice
were collected and processed for histology. Tissue sections were
stained with hematoxylin and eosin or Alizarin red using standard
procedures.
Chemical quantitation of calcium and phosphate
To quantify the mineral deposition in mouse tissues, muzzle skin bi-
opsies (right side) and abdominal aortawere harvestedanddecalcified
with 0.15mol/LHCl for 48hours at room temperature. The solubilized
calcium was then determined by colorimetric analysis using the ơ-
cresolphthalein complexone method (calcium (CPC) LiquiColor;
Stanbio Laboratory, Boerne, TX). The valueswere normalized to tissue
weight. Serum calcium concentrations were determined with the
same assay. Serum phosphate was measured by the Malachite Green
Phosphate Assay Kit (Bioassay Systems, Hayward, CA).
Microcomputed tomography
The microarchitecture of the distal trabecular bone and mid-shaft
region of the right femur was analyzed. A 1.2-mm-thick region
located proximal to the distal growth plate of femur and a 0.3-mm-
thick mid-shaft region of the femur were scanned at a 6 mm reso-
lution using the microcomputed tomography system (mCT35; Scanco
Medical AG, Bassersdorf, Switzerland). The microstructural param-
eters were obtained through three-dimensional reconstruction and
segmentation (using a Gaussian filter and a global threshold of 3685
Hounsfield units) using the manufacturer-provided software.
Cell cultures and induction of mineralization in vitro
NIH3T3 cells were routinely cultured in a DMEM growth medium in
the presence of 10% fetal bovine serum. At approximately 80%
confluence, the cells were switched to calcification-inducing me-
dium (DMEM supplemented with 2 mM Pi). The first day of culture
in a calcification-inducing medium was defined as day 0. PPi
(sodium pyrophosphate decahydrate, Thermo Fisher Scientific,
Q Li et al.
Treatment of GACI by BisphosphonatesPittsburgh, PA), ETD or AST, was added to some cultures at day 0 at a
concentration of 0.01, 0.1, 1.0, 10, or 100 mM, for additional 10
days. The medium was changed every other day. All experiments
were performed in quadruplicate. At day 10 of cell culture, the
media were removed, and the amount of calcium in the cell layer
was determined and normalized to the protein content (LaRusso
et al., 2009).
Statistical analysis
Comparisons between different groups of mice were performed us-
ing the two-sided Kruskal-Wallis nonparametric test. Fisher’s exact
test was used to determine proportional differences in different
groups. Statistical significance was reached with P < 0.05. All sta-
tistical computations were completed using SPSS version 15.0 soft-
ware (SPSS, Chicago, IL).
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